EIN 20-4284925

Quantum Leap Healthcare Collaborative

IRS 501(c) type
501(c)(3)
Num. employees
113
Year formed
2005
Most recent tax filings
2022-12-01
Description
To accelerate the transfer of high-impact research in clinical processes and systems technology into widespread adoption in the sectors of data management, clinical trial matching and sponsorship; therefore more quickly benefiting doctors and patients.
Total revenues
$47,253,845
2022
Total expenses
$47,240,395
2022
Total assets
$60,913,948
2022
Num. employees
113
2022

Program areas at Quantum Leap Healthcare Collaborative

I-spy trials: Quantum Leap sponsors the i-spy trials (investigation of serial studies to predict your therapeutic response with imaging and molecular analysis). I-spy has been re-engineering the approach to clinical trials, with a goal of getting the right drug to the right patient at the time when they will benefit most, and to achieve this faster than possible in previous trial models. Additionally, i-spy aims to significantly reduce the overall cost, time, and number of patients required to bring new drugs to market. The i-spy trial program integrates and links phase i (i-spy phase 1), phase ii (i-spy 2), and future phases to build a pipeline of novel agents and accelerate the process of identifying the subset of high-risk breast cancer patients that will benefit from these new agents, and get these drug into the clinic in a timely manner.
Breast cancer trials (bct) - launched in 2008, following a successful ucsf-nci sponsored research pilot, its mission is to make patient consideration of trials the norm vs. The exception. We believe that all patients should have access to the latest medical knowledge about breast cancer treatment as well as the opportunity to advance breast cancer research. Bct lists over 600 studies for people with newly diagnosed breast cancer, metastatic disease, or post-treatment survivors. It includes innovative trials of targeted and immunotherapies as well as observational studies looking at quality of life, genetic mutations, and breast cancer survivorship, accompanied by easy-to-read trial summaries.
During fiscal year 2020, the i-spy covid trial an adaptive platform trial, was designed to rapidly screen and confirm high impact treatments to reduce mortality and time on ventilators. This work is independent and equally as important as vaccine efforts. I-spy covid trial focuses on those patients whose reactions to the virus make them critically ill and, in many cases, results in death. The primary focus of the trial was to identify promising drugs that either neutralize the virus, help heal the lung damage from the virus (caused by adult respiratory distress syndrome or (ards) or to change the immune system reaction which results in illness (for younger people, this is especially important). The trial opened june 2020 and will continue to run until a drug or combinations of drugs, is found that prevents the necessity for ventilation treatment and eliminates death from the disease.

Who funds Quantum Leap Healthcare Collaborative

Grants from foundations and other nonprofits
GrantmakerDescriptionAmount
William K. Bowes Jr. FoundationAggregating and Visualizing Ehr and Epro Information$50,000
Schwab Charitable FundHuman Services$25,150
Morgan Stanley Global Impact Funding TrustUnrestricted General Support$17,000
...and 2 more grants received

Personnel at Quantum Leap Healthcare Collaborative

NameTitleCompensation
James PalazzoloChief Executive Officer$508,333
Adam AsareChief Data Officer$212,462
Karyn DigiorgioChief Collaboration Officer / Chief Operating Officer$278,506
Kathryn Watson-FeinerVice President of Finance and Administration / Director of Finance$305,989
Ruixio LuVice President Statistics , Clinical Data Management and Data Science / Senior Software Engineer$273,636
...and 12 more key personnel

Financials for Quantum Leap Healthcare Collaborative

RevenuesFYE 12/2022
Total grants, contributions, etc.$18,937,275
Program services$27,865,728
Investment income and dividends$517,557
Tax-exempt bond proceeds$0
Royalty revenue$0
Net rental income$0
Net gain from sale of non-inventory assets$-66,715
Net income from fundraising events$0
Net income from gaming activities$0
Net income from sales of inventory$0
Miscellaneous revenues$0
Total revenues$47,253,845

Form 990s for Quantum Leap Healthcare Collaborative

Fiscal year endingDate received by IRSFormPDF link
2022-122023-11-15990View PDF
2021-122023-06-26990View PDF
2021-122022-11-15990View PDF
2020-122021-11-15990View PDF
2019-122021-02-26990View PDF
...and 10 more Form 990s
Data update history
January 22, 2024
Posted financials
Added Form 990 for fiscal year 2022
January 15, 2024
Updated personnel
Identified 2 new personnel
January 1, 2024
Used new vendors
Identified 4 new vendors, including , , , and
December 28, 2023
Received grants
Identified 1 new grant, including a grant for $50,000 from William K. Bowes Jr. Foundation
August 1, 2023
Posted financials
Added Form 990 for fiscal year 2021
Nonprofit Types
UnionsResearch centersCharities
Issues
Science and technologyHuman servicesJobs and employmentPublic policy
Characteristics
Conducts researchReceives government fundingAuction fundraisersTax deductible donations
General information
Address
499 Illinois Ave 200
San Francisco, CA 94158
Metro area
San Francisco-Oakland-Berkeley, CA
Website URL
quantumleaphealth.org/ 
Phone
(415) 476-0271
IRS details
EIN
20-4284925
Fiscal year end
December
Taxreturn type
Form 990
Year formed
2005
Eligible to receive tax-deductible contributions (Pub 78)
Yes
Categorization
NTEE code, primary
J40: Labor unions, organizations
NAICS code, primary
5417: Scientific Research and Development Services
Parent/child status
Independent
Free account sign-up

Want updates when Quantum Leap Healthcare Collaborative has new information, or want to find more organizations like Quantum Leap Healthcare Collaborative?

Create free Cause IQ account